GSK shuffles execs and streamlines businesses as vaccines chief Connor heads for the exit

Now unburdened by its consumer health division, GSK is streamlining its drug and vaccines businesses and shuffling executives in turn.

On the quest to simplify its operations in a post-Haleon world, GSK is “bringing together our medicines and vaccines manufacturing networks, and equivalent commercial operations, in one place,” a company spokesperson said via email Tuesday.